Arizona State Retirement System Has $10.17 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Arizona State Retirement System cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,773 shares of the medical research company’s stock after selling 467 shares during the period. Arizona State Retirement System’s holdings in IQVIA were worth $10,174,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the 3rd quarter valued at about $27,000. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. lifted its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in IQVIA in the 3rd quarter valued at $57,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Truist Financial reiterated a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Stock Down 0.2 %

Shares of IQV opened at $185.45 on Friday. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $261.73. The firm has a 50 day simple moving average of $197.95 and a two-hundred day simple moving average of $213.47. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.70 billion, a P/E ratio of 24.73, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.